Incannex Healthcare (IXHL) EBITDA Margin (2024)
Incannex Healthcare's (IXHL) quarterly EBITDA Margin came in at 52566.67% in Q4 2024, down 665.58% quarter-over-quarter from 6866.22% in Q3 2024.
Incannex Healthcare (IXHL) EBITDA Margin (2024) Analysis & Trends
Incannex Healthcare has disclosed EBITDA Margin across 1 years of filings, most recently posting 52566.67% for Q4 2024.
- EBITDA Margin for Q4 2024 came in at 52566.67%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 54327.91% (changed N/A YoY), and the FY2025 annual result was 54275.58%, up 10019109.0% from the prior year.
- EBITDA Margin came in at 52566.67% for Q4 2024 at Incannex Healthcare, down from 6866.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 6866.22% in Q3 2024 to a low of 52566.67% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Incannex Healthcare | 45.81 Mn | 45.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -52,566.67% |
| Sep 30, 2024 | -6,866.22% |